Alexion Reaches New 52-Week High (ALXN)

NEW YORK ( TheStreet) -- Alexion Pharmaceuticals (Nasdaq: ALXN) hit a new 52-week high Tuesday as it is currently trading at $89.94, above its previous 52-week high of $89.90 with 1.3 million shares traded as of 3:35 p.m. ET. Average volume has been 1.2 million shares over the past 30 days.

Alexion has a market cap of $13.68 billion and is part of the health care sector and drugs industry. Shares are up 25.6% year to date as of the close of trading on Monday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. The company has a P/E ratio of 97.8, above the average drugs industry P/E ratio of 92.5 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Alexion as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Alexion Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Disney Tops Comcast Bid With Improved $71.3 Billion Approach for Fox

Disney Tops Comcast Bid With Improved $71.3 Billion Approach for Fox

With GE Dropped From the Dow, Be Selective About Industrials Stocks

With GE Dropped From the Dow, Be Selective About Industrials Stocks

MoviePass Parent's Stock Plunges as AMC Announces Rival Program

MoviePass Parent's Stock Plunges as AMC Announces Rival Program

Dow Rises as Blue-Chip Index Looks to End Losing Streak

Dow Rises as Blue-Chip Index Looks to End Losing Streak

3 Things to Know About the New Head of Amazon's Joint Stab at U.S. Healthcare

3 Things to Know About the New Head of Amazon's Joint Stab at U.S. Healthcare